Prostaglandin E2-Mediated Anabolic Effect of a Novel Inhibitor of Phosphodiesterase 4, XT-611, in the In Vitro Bone Marrow Culture
- 1 August 2003
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 18 (8) , 1471-1477
- https://doi.org/10.1359/jbmr.2003.18.8.1471
Abstract
The mechanism of osteoblast formation by a novel PDE4 inhibitor, XT-611, was studied in the in vitro bone marrow culture system. The compound potentiated the osteoblast differentiation through accumulation of cyclic AMP after autocrine stimulation of EP4 receptor by PGE2 in pro-osteoblastic cells. We previously reported that inhibitors of phosphodiesterase (PDE)4 isoenzyme increase osteoblast formation in an in vitro bone marrow culture system and inhibit bone loss in animal osteoporosis models. Here we investigated the mechanism of the effect of a novel PDE4 inhibitor, 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo[1,2-i]-purin-5-one (XT-611), on osteoblast formation in the in vitro bone marrow culture system. Rodent bone marrow cells were cultured in the presence of 0.2 mM ascorbic acid phosphate ester, 1 mM beta-glycerophosphate, and 10 nM dexamethasone for 10 days. Drug treatments were done for 24 h on day 3 of culture. PDE4 inhibitors, including XT-611, but not PDE3 and PDE5 inhibitors, increased mineralized nodule formation in rat and mouse bone marrow cell cultures. During culture of the bone marrow cells, prostaglandin E2 (PGE2) production increased with a peak on day 4, but the increase was completely inhibited by indomethacin, an unselective cyclo-oxygenase (COX) inhibitor. Spontaneous and XT-611-induced mineralized-nodule formation was also inhibited by indomethacin and COX-2 inhibitors, in a similar potential. Alkaline phosphatase-positive nodule formation in the absence or presence of XT-611 was inhibited by an antagonist of EP4 receptor, AH23848B, and synergistically potentiated by 11-deoxy-PGE1, but it was not influenced by other EP antagonists and agonists examined. The expression of PDE4 and EP4 mRNAs was observed in bone marrow cells. The effect of XT-611 was also confirmed to involve an increase of cyclic AMP and the cyclic AMP-dependent protein kinase pathway. These results suggest that PGE2 stimulates differentiation of osteoblast progenitor cells through the EP4 receptor in an autocrine manner, and the PDE4 inhibitor potentiates the differentiation by inhibiting hydrolysis of cyclic AMP in the cells.Keywords
This publication has 30 references indexed in Scilit:
- Effects of XT-44, a Phosphodiesterase 4 Inhibitor, in Osteoblastgenesis and Osteoclastgenesis in Culture and Its Therapeutic Effects in Rat Osteopenia ModelsThe Japanese Journal of Pharmacology, 1999
- Temporal Changes of mRNA Expression of Matrix Proteins and Parathyroid Hormone and Parathyroid Hormone–Related Protein (PTH/PTHrP) Receptor in Bone DevelopmentJournal of Bone and Mineral Research, 1997
- Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed PurinesJournal of Medicinal Chemistry, 1997
- Expression of prostaglandin E receptor subtypes in bone: Expression of EP2 in bone developmentBone, 1995
- Osteoporosis‐like Changes in Walker Carcinoma 256‐Bearing Rats, Not Accompanied with Hypercalcemia or Parathyroid Hormone‐related Protein ProductionJapanese Journal of Cancer Research, 1995
- Stimulation of prostaglandin e2 production by interleukin-1α and transforming growth factor α in osteoblastic MC3T3-E1 cellsJournal of Bone and Mineral Research, 1994
- Selective tracheal relaxation and phosphodiesterase-IV inhibition by xanthine derivativesEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cellsInternational Journal of Immunopharmacology, 1993
- Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female ratsBone, 1990
- Inhibition of a high affinity cyclic AMP phosphodiesterase and relaxation of canine tracheal smooth muscleBiochemical Pharmacology, 1982